Your browser doesn't support javascript.
loading
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman, Tim; Ozakbas, Serkan; Alroughani, Raed; Terzi, Murat; Hodgkinson, Suzanne; Laureys, Guy; Kalincik, Tomas; Der Walt, Anneke Van; Yamout, Bassem; Lechner-Scott, Jeannette; Soysal, Aysun; Kuhle, Jens; Sanchez-Menoyo, Jose Luis; Morgado, Yolanda Blanco; Spitaleri, Daniele LA; Pesch, Vincent van; Horakova, Dana; Ampapa, Radek; Patti, Francesco; Macdonell, Richard; Al-Asmi, Abdullah; Gerlach, Oliver; Oh, Jiwon; Altintas, Ayse; Tundia, Namita; Wong, Schiffon L; Butzkueven, Helmut.
Afiliação
  • Spelman T; MSBase Foundation, Melbourne, Australia.
  • Ozakbas S; Dokuz Eylul University, Izmir, Turkey.
  • Alroughani R; Amiri Hospital, Sharq, Kuwait.
  • Terzi M; Department of Neurology 19 Mayis University, Samsun, Turkey.
  • Hodgkinson S; Liverpool Hospital, Sydney, Australia.
  • Laureys G; University Hospital Ghent, Ghent, Belgium.
  • Kalincik T; MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
  • Der Walt AV; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Yamout B; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
  • Lechner-Scott J; Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates.
  • Soysal A; American University of Beirut Medical Center, Beirut, Lebanon.
  • Kuhle J; School of Medicine & Public Health, University of Newcastle, Newcastle, Australia.
  • Sanchez-Menoyo JL; Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia.
  • Morgado YB; Bakirkoy Education & Research Hospital for Psychiatric & Neurological Diseases, Istanbul, Turkey.
  • Spitaleri D; Multiple Sclerosis Centre, Neurology, Departments of Head, Spine & Neuromedicine, Biomedicine & Clinical Research, University Hospital Basel & University of Basel, Basel, Switzerland.
  • Pesch VV; Research Center for Clinical Neuroimmunology & Neuroscience (RC2NB), University Hospital & University of Basel, Switzerland.
  • Horakova D; Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain.
  • Ampapa R; Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Patti F; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.
  • Macdonell R; Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
  • Al-Asmi A; Department of Neurology & Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague & General University Hospital, Prague, Czech Republic.
  • Gerlach O; Nemocnice Jihlava, Jihlava, Czech Republic.
  • Oh J; Department of Medical & Surgical Sciences & Advanced Technologies, GF Ingrassia, Catania, Italy.
  • Altintas A; Department of Neurology, Austin Health, Melbourne, Australia.
  • Tundia N; Neurology Unit, Department of Medicine, College of Medicine & Health Sciences & Sultan Qaboos University Hospital, SQU, Al Khodh, Oman.
  • Wong SL; Academic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • Butzkueven H; School for Mental Health & Neuroscience, Maastricht University, Maastricht, The Netherlands.
Neurodegener Dis Manag ; 13(4): 215-221, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37287269
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Limite: Humans Idioma: En Revista: Neurodegener Dis Manag Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Limite: Humans Idioma: En Revista: Neurodegener Dis Manag Ano de publicação: 2023 Tipo de documento: Article